Changes in FDA Structure

HEHS-96-53R: Published: Dec 8, 1995. Publicly Released: Dec 8, 1995.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO examined changes in the Food and Drug Administration's (FDA) organizational structure since the new commissioner was appointed, focusing on changes in: (1) the number of staff positions in the Office of the Commissioner, staff offices, and product centers; and (2) FDA decisionmaking authority. GAO noted that between 1990 and 1995: (1) FDA increased its total staff by 20 percent; (2) the Office of the Commissioner received 4 percent of the staff increase, while staff offices received 11 percent and product centers received 85 percent of the increase; (3) the number of full-time equivalent (FTE) staff in the commissioner's office increased by 84 percent, while the number of staff reporting directly to the commissioner decreased; (4) FTE in staff offices increased by 21 percent, while FTE in product centers stayed about the same; and (5) there was no change in direction regarding the centralization of FDA decisionmaking authority, but some organizational changes decentralized product approval and centralized functions such as policy development.

Nov 30, 2020

Nov 18, 2020

Nov 17, 2020

Nov 13, 2020

Nov 12, 2020

Nov 4, 2020

Oct 26, 2020

Oct 8, 2020

Looking for more? Browse all our products here